Tang Capital Management LLC bought a new stake in shares of Molecular Partners AG (NASDAQ:MOLN – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 15,681 shares of the company's stock, valued at approximately $105,000.
Separately, Federated Hermes Inc. grew its position in Molecular Partners by 94.2% in the first quarter. Federated Hermes Inc. now owns 457,037 shares of the company's stock valued at $9,264,000 after acquiring an additional 221,743 shares during the period. 2.56% of the stock is owned by hedge funds and other institutional investors.
Get Molecular Partners alerts:Molecular Partners Price Performance
Molecular Partners stock traded up $0.20 on Wednesday, reaching $6.30. The company's stock had a trading volume of 238 shares, compared to its average volume of 2,403. Molecular Partners AG has a twelve month low of $5.50 and a twelve month high of $25.88. The business's fifty day moving average price is $6.55 and its 200 day moving average price is $6.45.
Molecular Partners Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
Recommended Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
- Occidental Petroleum: What Would Warren Buffett Do?
- Is Unity Software Earnings Fallout a Buying Opportunity?
- Why Wall Street Is Still So Constructive on Aecom Stock
Want to see what other hedge funds are holding MOLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Molecular Partners AG (NASDAQ:MOLN – Get Rating).
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.